外周T细胞淋巴瘤（PTCL）中组蛋白去乙酰化酶抑制剂的最新研究进展。
Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).
发表日期：2023 Aug 02
作者：
Guang Lu, Shikai Jin, Suwen Lin, Yuping Gong, Liwen Zhang, Jingwen Yang, Weiwei Mou, Jun Du
来源：
Epigenetics & Chromatin
摘要：
近年来，外周T细胞淋巴瘤（PTCLs）已证实是一组具有高度侵袭性的恶性肿瘤，通常预后不良，而PTCL的一线化疗疗效有限。目前，已经研究了几种新型靶向药物，包括组蛋白去乙酰化酶抑制剂（HDACis），以提高PTCL的治疗效果。几种HDACis，如罗米地平、贝利诺斯替和奇达麦特，在PTCL疗效和安全性上表现出了良好的临床效果。更多新型HDACis和新的联合治疗正在进行临床前或临床试验。基于下一代测序的突变分析可能有助于我们加深对表观遗传突变谱与相关靶向治疗之间关联性的理解。多靶点HDACis和基于HDACi的前药具有许多有前途的前景，并为药物设计提供了更多方向。©2023年，作者。
Peripheral T-cell lymphomas (PTCLs) are a group of highly aggressive malignancies with generally poor prognoses, and the first-line chemotherapy of PTCL has limited efficacy. Currently, several novel targeted agents, including histone deacetylase inhibitors (HDACis), have been investigated to improve the therapeutic outcome of PTCLs. Several HDACis, such as romidepsin, belinostat, and chidamide, have demonstrated favorable clinical efficacy and safety in PTCLs. More novel HDACis and new combination therapies are undergoing preclinical or clinical trials. Mutation analysis based on next-generation sequencing may advance our understanding of the correlation between epigenetic mutation profiles and relevant targeted therapies. Multitargeted HDACis and HDACi-based prodrugs hold promising futures and offer further directions for drug design.© 2023. The Author(s).